Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107
Cytokinetics announced the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy, is open to enrollment. This clinical trial is designed to assess the effect of CK-2127107 on multiple measures of muscle function. March 29, 2017